Material Agreements

Canton Strategic Holdings, Inc. entered into Underwriting Agreement with Clear Street LLC valued at Gross proceeds approximately $55 million; offering of 1,800,000 shares of common stock at $2.9200 pe (effective 2026-01-20).

“On January 20, 2026, Tharimmune, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Clear Street LLC, as the sole underwriter (the “Underwriter”), relating to an underwritten registered offering to a single institutional investor (the “Offering”) of (i) 1,800,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $2.9200 (the “Offering Price”), and (ii) certain pre-funded warrants (the “Pre-Funded Warrants”), at an offering price of Offering Price less $0.0001 per Pre-Funded Warrant, to purchase up to 17,000,000 shares of Common Stock.”

CDT Equity Inc. entered into Purchase Agreement with an institutional investor valued at up to $25 million (effective 2026-01-16).

“On January 16, 2026, CDT Equity Inc. (the “Company”), entered into a directed stock purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) relating to an equity line of credit facility (the “ELOC”).”

Israel Acquisitions Corp amended Trust Agreement Amendment with Equiniti Trust Company, LLC valued at Amendment to extend the business combination deadline from January 18, 2026 to January 18, 2027, all (effective 2026-01-16).

“As approved by the shareholders of Israel Acquisitions Corp (the “ Company ”), by special resolution, at an extraordinary general meeting of shareholders held on January 16, 2026 (the “ Meeting ”), on January 16, 2026, the Company entered into an amendment (the “ Trust Agreement Amendment ”) to the Investment Management Trust Agreement, dated as of January 12, 2023 and amended on January 8, 2024 by Amendment No. 1 and on January 6, 2025 by Amendment No. 2, with Equiniti Trust Company, LLC (f/k/a American Stock Transfer & Trust Company) (the “ Trustee ”).”

Strive, Inc. entered into Underwriting Agreement with Barclays Capital Inc. and Cantor Fitzgerald & Co., as the joint book-running managers and representatives of the several underwriters valued at approximately $118.8 million (effective 2026-01-22).

“On January 22, 2026, Strive, Inc. (“Strive” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc. and Cantor Fitzgerald & Co., as the joint book-running managers and representatives of the several underwriters (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) registered under the Securities Act of 1933, as amended (the “Securities Act”), of 1,320,000 shares (the “Shares”) of the Company’s Variable Rate Series A Perpetual Preferred Stock, $0.001 par value per share (the “SATA Stock”), an upsize over the $150 million transaction size previously announced when taken together with the anticipated privately negotiated notes exchanges , at a public offering price of $90 per share.”

Sealy Industrial Partners IV, LP amended First Amended and Restated Credit Agreement with KeyBank National Association valued at $150 million (effective 2026-01-15).

“On January 15, 2026, Sealy Industrial Partners IV OP, LP (the “Borrower”), a Georgia limited partnership and indirect subsidiary of Sealy Industrial Partners IV, LP (the “Registrant”), entered into that certain First Amended and Restated Credit Agreement (the “A&R Credit Agreement”) with KeyBank National Association (“KeyBank")”

Phillip Street BDC LLC entered into Fifth Amendment to Secured Credit Facility with Ally Bank, as administrative agent, arranger and swingline lender, and State Street Bank and Trust Company, as collateral custodian, and the lenders party thereto valued at $750,000,000 (effective 2026-01-16).

“On January 16, 2026, Phillip Street Middle Market Lending Investments LLC ("SPV"), an indirectly wholly owned subsidiary of Phillip Street Middle Market Lending Fund LLC (the "Company") entered into a fifth amendment (the "Amendment") to its secured credit facility, dated as of February 10, 2023 (as amended, supplemented or otherwise modified and in effect from time to time, including by the Amendment, the "Ally Credit Facility") by and among the Company, as collateral manager and transferor, Phillip Street Middle Market Lending Investment Holdings LLC, as equityholder, the SPV, as borrower, each of the lenders from time to time party thereto (the "Lenders"), Ally Bank, as administrative agent, arranger and swingline lender, and State Street Bank and Trust Company, as collateral custodian.”

Worthington Steel, Inc. entered into BCA with Klöckner & Co SE valued at €11.00 for each Kloeckner Share (effective 2026-01-15).

“On January 15, 2026, Worthington Steel, Inc., an Ohio corporation (the “ Company ” or “ Worthington Steel ”), and Worthington Steel GmbH, a limited liability company established under German law ( Gesellschaft mit beschränkter Haftung ) (“ Bidder ”), and Klöckner & Co SE, a European stock corporation ( societas europaea ) organized under the laws of Germany (“ Kloeckner ”), entered into a business combination agreement (the “ BCA ”).”

Bayview Acquisition Corp amended Amendment No. 3 to the Merger Agreement with the parties to the Merger Agreement (effective 2026-01-21).

“On January 21, 2026, the parties to the Merger Agreement entered into Amendment No. 3 to the Merger Agreement (the “Third Amendment”), pursuant to which the Outside Closing Date (as defined in the Merger Agreement) was extended to June 15, 2026.”

Anteris Technologies Global Corp. entered into Purchase Agreement with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc valued at approximately $90.0 million (effective 2026-01-20).

“On January 20, 2026, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc (the “Investor”), pursuant to which the Company agreed to issue and sell (the “Private Placement”) to the Investor 15,652,173 shares of Common Stock of the Company (the “PIPE Shares”) at a purchase price of $5.75 per PIPE Share.”

Anteris Technologies Global Corp. entered into Underwriting Agreement with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein valued at approximately $320 million (effective 2026-01-20).

“On January 20, 2026, Anteris Technologies Global Corp. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (the “Offering”) 34,782,609 shares (the “Firm Stock”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $5.75 per share.”

SharonAI Holdings Inc. entered into Membership Interest Purchase Agreement with New Era Energy & Digital Inc. (NUAI) valued at an aggregate of $70,000,000 (effective 2026-01-16).

“On January 16, 2026, SharonAI Inc., a subsidiary of SharonAI Inc. Holdings Inc. (“we,” “us,” the “Company” or “SharonAI”), entered into a Membership Interest Purchase Agreement (“Purchase Agreement”) for, and closed the sale of, SharonAI’s sale of 100% of its 50% interest (“Membership Interests”) in Texas Critical Data Centers LLC (“TCDC”) to New Era Energy & Digital Inc. (“NUAI”).”

X3 Acquisition Corp. Ltd. entered into Private Placement Warrants Purchase Agreement with X3 Acquisition Management LLC (the Sponsor) (effective 2026-01-20).

“● Private Placement Warrants Purchase Agreement, dated January 20, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 hereto and incorporated herein by reference;”

X3 Acquisition Corp. Ltd. entered into Registration Rights Agreement with the Sponsor and certain security holders of the Company (effective 2026-01-20).

“● Registration Rights Agreement, dated January 20, 2026, by and among the Company, the Sponsor and certain security holders of the Company, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference;”

X3 Acquisition Corp. Ltd. entered into Investment Management Trust Agreement with Continental Stock Transfer & Trust Company, as trustee (effective 2026-01-20).

“● Investment Management Trust Agreement, dated January 20, 2026, by and between the Company and Continental Stock Transfer & Trust Company, as trustee, a copy of which is attached as Exhibit 10.2 hereto and incorporated herein by reference;”

X3 Acquisition Corp. Ltd. entered into Warrant Agreement with Continental Stock Transfer & Trust Company, as warrant agent (effective 2026-01-20).

“● Warrant Agreement, dated January 20, 2026, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent, a copy of which is attached as Exhibit 4.1 hereto and incorporated herein by reference;”

X3 Acquisition Corp. Ltd. entered into Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated, as representative of the underwriters valued at $200,000,000 (effective 2026-01-20).

“● Underwriting Agreement, dated January 20, 2026, by and between the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the underwriters in the IPO (“Stifel”), a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference;”

Light & Wonder, Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A. valued at New tranche of $2,134,562,718.75 term loans; interest rate reductions to 2.00% (term benchmark) and (effective 2026-01-22).

“On January 22, 2026, Light and Wonder International, Inc. (" L&WI "), a Delaware corporation and wholly owned subsidiary of Light & Wonder, Inc., a Nevada corporation (the " Company "), entered into that certain Amendment No. 4 (" Amendment No. 4 ") to the Credit Agreement dated April 14, 2022 by and among the Company, L&WI, the several banks and other financial institutions or entities from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, issuing lender and swingline lender (as amended by the Amendment No. 1, dated as of January 16, 2024, as further amended by the Amendment No. 2, dated as of July 17, 2024, as further amended by the Amendment No. 3, dated as of February 10, 2025, and as further amended, supplemented, amended and restated or otherwise modified from time to time, the " Credit Agreement ").”

ASSURED GUARANTY LTD entered into Purchase Agreement with Long Duration Financing Sub LLC, Blue Owl GP Stakes V (B) LP, Axonic Funding (Cayman) LP, Axonic Capital LLC valued at cash consideration of approximately $158 million (effective 2026-01-21).

“On January 21, 2026, Assured Guaranty UK Holdings Ltd (the “Purchaser”), a wholly owned subsidiary of Assured Guaranty Ltd. (“AGL” and, together with its affiliates, “Assured Guaranty”) entered into a sale and purchase agreement (the “Purchase Agreement”) with Long Duration Financing Sub LLC (“Long Duration”), Blue Owl GP Stakes V (B) LP (the “Blue Owl Seller”), Axonic Funding (Cayman) LP (the “Axonic Funding Seller”) and Axonic Capital LLC (the “Axonic Capital Seller” and, together with Long Duration, the Blue Owl Seller and the Axonic Funding Seller, the “Sellers”), pursuant to which the Purchaser agreed to purchase, and the Sellers agreed to sell, all of the issued and outstanding share capital of Warwick Company (UK) Limited (“Warwick Holdings” and, together with its subsidiaries, “Warwick Group”) for cash consideration of approximately $158 million (the “Purchase Price”) (the “Transaction”).”

Ocugen, Inc. entered into Underwriting Agreement with Oppenheimer & Co. Inc. valued at 15,000,000 shares of common stock at $1.50 per share, net proceeds approximately $20.8 million (effective 2026-01-20).

“On January 20, 2026, Ocugen, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Oppenheimer & Co. Inc. (the “ Underwriter ”), pursuant to which the Company agreed to issue and sell to the Underwriter, in an offering (the “ Offering ”) 15,000,000 shares of the Company’s common stock, par value $0.01 per share (the “ Common Stock ”), at an offering price of $1.50 per share (the “ Offering Price ”).”

Archrock, Inc. entered into Indenture with Archrock Services, L.P., Archrock Partners Finance Corp., Archrock, Inc., certain subsidiaries of the Parent, and Regions Bank, as trustee valued at $800,000,000 aggregate principal amount (effective 2026-01-21).

“On January 21, 2026, Archrock Services, L.P. (the “Partnership”), and its wholly owned subsidiary, Archrock Partners Finance Corp. (“Finance Corp.” and, together with the Partnership, the “Issuers”), completed a private offering (the “Notes Offering”) of $800,000,000 aggregate principal amount of 6.000% senior notes due 2034 (the “Notes”), along with the related guarantees of the Notes (the “Guarantees”).”

Venus Concept Inc. entered into Twenty Fourth Bridge Loan Amendment with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP valued at Maturity date of the Bridge Loan is extended from January 14, 2026 to January 31, 2026 and certain m (effective 2026-01-14).

“On January 14, 2026, the Loan Parties entered into a Twenty Fourth Bridge Loan Amendment Agreement with the Lenders (the “Twenty Fourth Bridge Loan Amendment”).”

Venus Concept Inc. entered into Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP valued at Certain minimum liquidity requirements under the MSLP Loan Agreement are waived through January 31, (effective 2026-01-14).

“On January 14, 2026, Venus Concept Inc. (the “Company”), Venus Concept USA, Inc., a wholly-owned subsidiary of the Company (“Venus USA” or “Borrower”), Venus Concept Canada Corp., a wholly-owned Canadian subsidiary of the Company (“Venus Canada”), and Venus Concept Ltd., a wholly-owned Israeli subsidiary of the Company (“Venus Israel” and together with the Company, Venus USA and Venus Canada, the “Loan Parties”), entered into a Consent Agreement with Madryn Health Partners, LP (“Madryn”) and Madryn Health Partners (Cayman Master), LP (“Madryn Cayman,” and together with Madryn, the “Lenders” or the “Holders”) (the “Consent Agreement”).”

MacKenzie Realty Capital, Inc. entered into Secured Note #3 with Streeterville Capital, LLC valued at in the aggregate principal amount of $1,635,000 (effective 2026-01-15).

“On January 15, 2026, the Company issued to the Investor a secured promissory note under the Note Purchase Agreement in the aggregate principal amount of $1,635,000 (“Secured Note #3”).”

Vroom, Inc. entered into Preferred Unit Purchase Agreement with SPE Holdings 2026-1 valued at Issue 15,000 Series A and 7,500 Series B preferred units for $22,500,000 gross proceeds (effective 2026-01-16).

“On January 16, 2026, Vroom Automotive LLC (“ Vroom Automotive ”), a Delaware limited liability company and a subsidiary of Vroom, Inc. (the “ Company ”), holding intellectual property licenses and other financial assets, issued to SPE Holdings 2026-1, a Delaware statutory trust (“ SPE Holdings ”), 15,000 newly issued Series A preferred units (the “ Series A Preferred Units ”) and 7,500 newly issued Series B preferred units (the “ Series B Preferred Units ” and together with the Series A Preferred Units, the “ Vroom Automotive Preferred Units ”) for aggregate gross proceeds of $22,500,000.”

BridgeBio Pharma, Inc. entered into 0.75% Convertible Senior Notes due 2033 Indenture with U.S. Bank Trust Company, National Association valued at $632,500,000 aggregate principal amount (effective 2026-01-21).

“On January 21, 2026, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).”

Reliance Global Group, Inc. entered into Note with Enquantum Ltd. valued at $166,000 (effective 2026-01-15).

“On January 15, 2026, Reliance Global Group, Inc. (the “Company”) entered into a secured convertible promissory note (the “Note”) with Enquantum Ltd. (“Enquantum”) pursuant to which the Company advanced to Enquantum $166,000 (the “Principal Amount”).”

SOCIETY PASS INCORPORATED. entered into Sapience AI Incorporated Subscription Agreement with Sapience AI Incorporated and Ascendance Group Limited valued at US$8,801,430 (effective 2026-01-19).

“On the same date, the Company entered into a subscription agreement with Sapience AI Incorporated, a Nevada corporation (“Sapience”), and Ascendance. Pursuant to the agreement, the Subscribers agreed to purchase an aggregate of 10,234 shares of Sapience’s common stock, par value US$0.0001 per share, at a purchase price of US$860.00 per share, for an aggregate consideration of US$8,801,430.”

SOCIETY PASS INCORPORATED. entered into Gorilla Networks Pte Ltd Subscription Agreement with Gorilla Networks Pte Ltd and Ascendance Group Limited valued at US$1,898,577 (effective 2026-01-19).

“On January 19, 2026, Society Pass Incorporated (the “Company”) entered into a subscription agreement with Gorilla Networks Pte Ltd, a company incorporated under the laws of the Republic of Singapore (“Gorilla”), and Ascendance Group Limited, an exempted company incorporated under the laws of the Cayman Islands (“Ascendance,” and together with the Company, the “Subscribers”). Pursuant to the agreement, the Subscribers agreed to purchase an aggregate of 7,031,765 shares of Gorilla’s common stock at a purchase price of US$0.27 per share, for an aggregate consideration of US$1,898,577.”

Serve Robotics Inc. /DE/ entered into Merger Agreement with Diligent Robotics, Inc. valued at $29.0 million (effective 2026-01-19).

“On January 19, 2026, Serve Robotics Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Delight Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of the Company (“Merger Sub”), Diligent Robotics, Inc. (“Diligent”)”

HPS Corporate Lending Fund amended Fourth Amendment to Credit Agreement with HLEND Holdings D, L.P. valued at Extension of reinvestment period to January 20, 2029; extension of final maturity date to January 20 (effective 2026-01-20).

“On January 20, 2026, HPS Corporate Lending Fund (the “ Fund ”) entered into that certain Fourth Amendment to Credit Agreement (the “ Amendment ”) among the Fund, as equityholder and collateral manager, HLEND Holdings D, L.P., as borrower (the “ Borrower ”), U.S. Bank Trust Company, National Association, as collateral agent, BNP Paribas, as administrative agent, and the lenders party thereto, amending that certain Revolving Credit and Security Agreement, dated as of March 31, 2023, among the Fund, as equityholder and collateral manager, the Borrower, U.S. Bank Trust Company, National Association, as collateral agent, BNP Paribas, as administrative agent, and the lenders from time to time party thereto (as amended and supplemented, the “ Funding Facility ”).”

Perfect Moment Ltd. entered into Securities Purchase Agreement with X3 Higher Moment Fund LLC (effective 2025-08-27).

“On August 27, 2025, Perfect Moment Ltd. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with X3 Higher Moment Fund LLC (the “X3”) to issue and sell (i) 3,172,858 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”) and (ii) a warrant (the “Warrant 1”) to purchase up to 3,204,908 shares of Common Stock”

GENESCO INC amended Fourth Amendment to Fourth Amended and Restated Credit Agreement with Bank of America, N.A., as agent, and the lenders party thereto (effective 2026-01-16).

“On January 16, 2026, Genesco Inc., a Tennessee corporation (the “ Company ”), entered into a Fourth Amendment to Fourth Amended and Restated Credit Agreement (the “ Fourth Amendment ”) by and among the Company, certain subsidiaries of the Company party thereto (collectively with the Company, the “ Borrowers ”), the lenders party thereto (the “ Lenders ”), and Bank of America, N.A., as agent, amending the Fourth Amended and Restated Credit Agreement, dated as of January 31, 2018 (the “ Credit Agreement ”), by and among the Borrowers, the Lenders party thereto and Bank of America, N.A., as Agent.”

Golub Capital Private Credit Fund entered into Master Loan Sale Agreement (effective 2026-01-14).

“Under the terms of the loan sale agreement entered into upon the Closing Date (the "Master Loan Sale Agreement") that provides for the sale of assets from time to time on and after the Closing Date”

Golub Capital Private Credit Fund entered into Note Purchase Agreement with BofA Securities, Inc. valued at $400,150,000 (effective 2026-01-14).

“On January 14, 2026 (the "Closing Date"), GCRED BSL CLO 1 (the "2026 Issuer"), an indirect, wholly owned and primarily controlled subsidiary of Golub Capital Private Credit Fund (the "Company"), completed a $400,150,000 term debt securitization”

High Roller Technologies, Inc. entered into Placement Agent Agreement with ThinkEquity LLC valued at approximately $25 million (effective 2026-01-19).

“On January 19, 2026, High Roller Technologies, Inc. (the “Company”), entered into a placement agent agreement (the “Placement Agent Agreement”) with ThinkEquity LLC (“the “Placement Agent”), pursuant to which the Company agreed to issue and sell directly to several investors, in a registered direct offering (the “Offering”) an aggregate of 1,892,506 shares (the “Shares”) of the common stock, par value $0.001 (the “Common Stock”), at an offering price of $13.21 per Share.”

enGene Therapeutics Inc. entered into Second Amendment with Hercules Capital, Inc. valued at up to $125 million (effective 2026-01-20).

“On January 20, 2026 (the “Closing Date”), enGene Holdings Inc. (the “Company”, and together with its subsidiaries enGene Inc. and enGene USA, Inc., collectively, the “Borrower”) entered into a Second Amendment (the “Second Amendment”) to its Amended and Restated Loan and Security Agreement”

LGAM Private Credit LLC amended Citibank Funding Facility with Citibank, N.A. valued at $500,000,000 (effective 2026-01-15).

“On January 15, 2026, LGAM Financing SPV LLC (“LGAM SPV”), a wholly owned subsidiary of LGAM Private Credit LLC (the “Company”), agreed in writing with Citibank, N.A., as Administrative Agent (the “Administrative Agent”) pursuant to Section 2.22 of that certain Credit and Security Agreement, dated as of December 4, 2023 (as amended, restated or otherwise modified from time to time, the “Citibank Funding Facility”), by and among LGAM SPV, as Borrower, the Company, as Collateral Manager and Equityholder, the Lenders party thereto, the Administrative Agent, U.S. Bank Trust Company, National Association, as Collateral Administrator and as Collateral Agent, and U.S. Bank National Association, as Document Custodian, to upsize the Citibank Funding Facility (the “Upsize”).”

LISATA THERAPEUTICS, INC. entered into Binding Term Sheet with Kuva Labs Inc. valued at $4.00 per share in cash plus two contingent value rights (CVRs) totaling up to $2.00 per share (effective 2026-01-20).

“On January 20, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ Lisata ”), entered into a binding term sheet (the “ Term Sheet ”) with Kuva Labs Inc., a Delaware corporation (“ Kuva ”), pursuant to which Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata by Kuva (the “ Purchase Agreement ”) whereby Kuva will commence a tender offer to purchase, on a fully-diluted basis, all of the outstanding shares of common stock of Lisata (the “ Shares ”) at a price of $4.00 per Share in cash (the “ Offer ”).”

Global Asset Management Group, Inc. entered into Placement Agent Agreement with Alpine Securities Corporation valued at $100,000 of restricted Common shares at $.20 per share (effective 2026-01-15).

“On January 15, 2026, the Registrant entered into a non-exclusive Placement Agent Agreement with Alpine Securities Corporation in connection with a proposed offering of Common Stock of the Company.”

NATHANS FAMOUS, INC. entered into Agreement and Plan of Merger with Smithfield Foods, Inc. and Boardwalk Merger Sub Inc. (effective 2026-01-20).

“On January 20, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Buyer and Boardwalk Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Buyer (“Merger Sub”).”

ALLEGRO MICROSYSTEMS, INC. amended Fourth Amendment with Morgan Stanley Senior Funding, Inc. valued at $285 million (effective 2026-01-21).

“On January 21, 2026, Allegro MicroSystems, Inc. (the “Company”) entered into an Amendment No. 4 (the “Fourth Amendment”) to the Credit Agreement, dated as of June 21, 2023”

Pursuit Attractions & Hospitality, Inc. entered into Purchase Agreement with Flyover Attractions B.V. valued at $78.4 million (effective 2026-01-21).

“On January 21, 2026, Pursuit Attractions and Hospitality, Inc. (the “Company”) entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Pursuit Investment Holdings, Inc., a Delaware corporation (the “U.S. Seller”), and Brewster Inc., an Alberta corporation (together with the Company and U.S. Seller, the “Sellers”), Flyover Attractions B.V. (the “Buyer”) and Brogent Technologies, Inc., as guarantor, pursuant to which the Sellers have agreed to sell to the Buyer all of the outstanding equity interests in the subsidiaries comprising the Company’s Flyover flying theater attractions business (the “Transaction”).”

BOYD GAMING CORP terminated Credit Agreement with Bank of America, N.A., as administrative agent, collateral agent and letter of credit issuer, Wells Fargo Bank, National Association, as swingline lender, and certain other financial institutions party thereto as lenders (effective 2026-01-21).

“The New Credit Agreement amends and restates that certain Credit Agreement (the “Prior Credit Agreement”), dated as of March 2, 2022, among the Company, Bank of America, N.A., as administrative agent, collateral agent and letter of credit issuer, Wells Fargo Bank, National Association, as swingline lender, and certain other financial institutions party thereto as lenders.”

BOYD GAMING CORP amended Amended and Restated Credit Agreement with Bank of America, N.A., as administrative agent, collateral agent and letter of credit issuer, Wells Fargo Bank, National Association, as swingline lender, and certain other financial institutions party thereto as lenders valued at a $1,450.0 million senior secured revolving credit facility and a $1,200.0 million senior secured te (effective 2026-01-21).

“On January 21, 2026 (the “Closing Date”), Boyd Gaming Corporation (the “Company”) entered into that certain Amended and Restated Credit Agreement (the “New Credit Agreement”) among the Company, certain direct and indirect subsidiaries of the Company as guarantors (the “Guarantors”), Bank of America, N.A., as administrative agent, collateral agent and letter of credit issuer, Wells Fargo Bank, National Association, as swingline lender, and certain other financial institutions party thereto as lenders.”

SMITHFIELD FOODS INC entered into Agreement and Plan of Merger with Nathan's Famous, Inc. and Boardwalk Merger Sub Inc. (effective 2026-01-20).

“On January 20, 2026, Smithfield Foods, Inc. (“ Smithfield ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Nathan’s Famous, Inc. (“ Nathan’s ”), and Boardwalk Merger Sub Inc., a wholly owned subsidiary of Smithfield (“ Merger Sub ”).”

NOVAVAX INC entered into License and Option Agreement with Pfizer Inc. valued at $30 million (effective 2026-01-15).

“On January 15, 2026, (the “Effective Date”), Novavax, Inc. (the “Company”) entered into a License and Option Agreement (the “License and Option Agreement”) with Pfizer Inc. (“Pfizer”)”

NETFLIX INC amended Amended and Restated Agreement and Plan of Merger with Warner Bros. Discovery, Inc. (effective 2026-01-19).

“On January 19, 2026, Netflix, Inc., a Delaware corporation (“Netflix”), Nightingale Sub, Inc., a Delaware corporation and wholly owned subsidiary of Netflix (“Merger Sub”), Warner Bros. Discovery, Inc., a Delaware corporation (“WBD”), and New Topco 25, Inc., a newly formed Delaware corporation and wholly owned subsidiary of WBD (“Newco”), entered into an Amended and Restated Agreement and Plan of Merger (the “Amended and Restated Merger Agreement”), which amends and restates in its entirety the Agreement and Plan of Merger, dated as of December 4, 2025, by and among Netflix, Merger Sub, WBD and Newco (the “Original Merger Agreement”).”

COMMUNITY HEALTH SYSTEMS INC entered into Asset Purchase Agreement with The Health Care Authority of the City of Huntsville, d/b/a Huntsville Hospital Health System valued at $450 million (effective 2026-01-20).

“On January 20, 2026, CHS/Community Health Systems, Inc. (“CHS”), a wholly-owned subsidiary of Community Health Systems, Inc. (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with The Health Care Authority of the City of Huntsville, d/b/a Huntsville Hospital Health System (the “Purchaser”).”

Veradigm Inc. amended Second Amendment to Stockholder Agreement with Charles Myers and Jessica Myers (Myers Parties) valued at Extension of Termination Date to July 26, 2026, with possible further extension to January 26, 2027 (effective 2026-01-15).

“on January 15, 2026, the Company entered into a Second Amendment to the Stockholder Agreement with the Myers Parties (the “Second Stockholder Agreement Amendment”) extending the Termination Date (as defined therein) to July 26, 2026.”